{"pressReleases":{"preSearchContent":"","tabbedVersion":false,"tabbedVersionLatest":null,"tabbedVersionArchived":null,"tabbedArchivedStartDate":null,"hideArchiveKeyLine":false,"heading":"報道関係の皆さま向けのお知らせ（プレスリリース）","intro":"

日本の最新および過去のプレスリリースがご覧になれます。
グローバルのプレスリリースについてはこちら（英語）をご覧ください。

","categories":{"グローバル":"グローバル","日本":"日本"},"enabledFilters":["dateRange","category","text"],"captions":{"showMore":null,"mostRecent":"新しい順","mostRelevant":"関連性順","search":"Search","download":"Download","resetSearch":"Reset search","clear":"Clear all","noResults":"申し訳ありません。ご希望の条件に合う検索結果が見つかりませんでした。","resultsAvailable":null,"cancel":"Cancel","apply":"Apply","nowPlaying":null,"paginationAriaLabel":"Pagination","previous":"","previousAriaLabel":"Go to previous page","next":"","nextAriaLabel":"Go to next page","goToPageAriaLabel":"Go to page ##PAGE##","currentPageAriaLabel":"Page","numberOfResultsPerPage":"表示件数","playVideo":"Play video {title}","filterBy":"Filter By:","sortBy":"Sort By:","select":"Select","category":"カテゴリー","dateRange":"Select date range","dateRangeBubbleText":"Date range","all":"All","lastWeek":"Last week","lastMonth":"Last month","lastSix":"Last 6 months","searchPrompt":"検索する","resultsText":"{filteredCount} out of {totalCount} results","tabbedArchivedSearchLabel":"","tabbedSearchBarLatestLabel":"","tabbedLatestTabDescription":"","tabbedVersionArchivedDescription":""},"counts":{"totalFound":291,"totalPages":15,"currentPage":1,"pageSize":20},"endpoint":"/api/search/pressreleases?parentId=3058&culture=ja-JP","minimumSearchDate":null,"results":[{"headline":"GSKのベピロビルセン、統計学的に有意な機能的治癒の達成割合を示し、B型肝炎ウイルス持続感染の治療に新たな可能性を示唆","description":"GSK（本社：英国）は、HBV持続感染の治療を目的として開発中の、アンチセンスオリゴヌクレオチド（ASO）であるベピロビルセンに関する主要試験データを発表しました。","url":"/ja-jp/news/press-releases/20260612-bepirovirsen-achieves-unprecedented-functional-cure-rates-with-potential-to-redefine-treatment-for-chronic-hepatitis-b/","datePublished":"2026年6月12日","dateTime":"2026-06-12T11:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["グローバル"],"tags":[]},{"headline":"GSK、RSウイルスワクチン「アレックスビー筋注用」の接種対象者拡大 ～RSウイルスによる感染症が重症化するリスクの高い18～49歳の成人を対象とする用法及び用量追加に係る製造販売承認事項一部変更承認を取得～","description":"グラクソ・スミスクライン株式会社（本社：東京都港区、代表取締役社長：ポール・リレット、以下GSK）は、本日、「アレックスビー筋注用」（以下、アレックスビー）について、RSウイルスによる感染症が重症化するリスクの高い18～49歳の成人を対象として、用法及び用量追加に係る製造販売承認","url":"/ja-jp/news/press-releases/20260518-arexvy/","datePublished":"2026年5月18日","dateTime":"2026-05-18T15:08:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["日本"],"tags":[]},{"headline":"2026年第1四半期 GSK、2026年第1四半期業績発表　好調な業績と滑り出し","description":"スペシャリティ医薬品の好調な業績が、売上およびコア営業利益の成長を牽引","url":"/ja-jp/news/press-releases/20260515_q1-2026/","datePublished":"2026年5月15日","dateTime":"2026-05-15T11:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["グローバル"],"tags":[]},{"headline":"GSK、気管支喘息および鼻茸を伴う慢性副鼻腔炎の2つを適応とする「エキシデンサー皮下注100mgペン」「エキシデンサー皮下注100mgシリンジ」発売のお知らせ","description":"グラクソ・スミスクライン株式会社（本社：東京都港区、代表取締役社長：ポール・リレット、以下 GSK）は、本日、気管支喘息（既存治療によっても喘息症状をコントロールできない重症又は難治の患者に限る）、および、鼻茸を伴う慢性副鼻腔炎（既存治療で効果不十分な患者に限る）の2つを適応とす","url":"/ja-jp/news/press-releases/20260415-exdensur/","datePublished":"2026年4月15日","dateTime":"2026-04-15T10:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["日本"],"tags":[]},{"headline":"GSKのB7-H3を標的とした抗体薬物複合体であるrisvutatug rezetecan、日本で小細胞肺がんを対象として希少疾病用医薬品に指定","description":"グラクソ・スミスクライン株式会社（本社：東京都港区、代表取締役社長：ポール・リレット、以下GSK）は、このたびB7-H3を標的とする抗体薬物複合体（antibody-drug conjugate、以下ADC）であるrisvutatug rezetecan（以下Ris-Rez）が、","url":"/ja-jp/news/press-releases/20260325-risvutatug-rezetecan/","datePublished":"2026年3月25日","dateTime":"2026-03-25T11:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["日本"],"tags":[]},{"headline":"GSK、再発又は難治性の多発性骨髄腫に対する治療薬「ブーレンレップ点滴静注用100mg」発売のお知らせ","description":"グラクソ・スミスクライン株式会社（本社：東京都港区、代表取締役社長：ポール・リレット、以下GSK）は、本日、「再発又は難治性の多発性骨髄腫」を効能又は効果として治療薬「ブーレンレップ点滴静注用100mg」（一般名：ベランタマブ　マホドチン（遺伝子組換え）、以下ブーレンレップ）を発","url":"/ja-jp/news/press-releases/20260318-blenrep_japan_launch/","datePublished":"2026年3月18日","dateTime":"2026-03-18T11:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["日本"],"tags":[]},{"headline":"GSK、B型肝炎ウイルス持続感染に対する治療薬としてベピロビルセンを日本で承認申請","description":"グラクソ・スミスクライン株式会社（本社：東京都港区、代表取締役社長：ポール・リレット、以下GSK）は、本日、成人のB型肝炎ウイルス（Hepatitis B virus、以下HBV）持続感染の治療薬として開発中の、アンチセンスオリゴヌクレオチド（antisense oligonuc","url":"/ja-jp/news/press-releases/20260226-bepirovirsen/","datePublished":"2026年2月26日","dateTime":"2026-02-26T16:05:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["日本"],"tags":[]},{"headline":"GSK、2025年通年および第4四半期業績発表　2025年の好調な業績を発表し、長期見通しを改めて確認","description":"スペシャリティ医薬品の業績が好調で、売上、利益、収益が増加","url":"/ja-jp/news/press-releases/20260213_fy2025/","datePublished":"2026年2月13日","dateTime":"2026-02-13T14:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["グローバル"],"tags":[]},{"headline":"グラクソ・スミスクライン株式会社 取締役人事についてのお知らせ","description":"グラクソ・スミスクライン株式会社（本社：東京都港区、代表取締役社長：ポール・リレット）は取締役人事に関して下記の通りお知らせいたします。","url":"/ja-jp/news/press-releases/20260202-hr/","datePublished":"2026年2月2日","dateTime":"2026-02-02T10:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["日本"],"tags":[]},{"headline":"グラクソ・スミスクライン株式会社 取締役人事についてのお知らせ","description":"グラクソ・スミスクライン株式会社（本社：東京都港区、代表取締役社長：ポール・リレット）は取締役人事に関して下記の通りお知らせいたします。","url":"/ja-jp/news/press-releases/20260105-hr/","datePublished":"2026年1月5日","dateTime":"2026-01-05T14:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["日本"],"tags":[]},{"headline":"GSK、エキシデンサー（デペモキマブ）における気管支喘息および鼻茸を伴う慢性副鼻腔炎の2つの適応を日本で承認取得","description":"グラクソ・スミスクライン株式会社（本社：東京都港区、代表取締役社長：ポール・リレット、以下GSK）は本日、エキシデンサー皮下注100mgペン及び同皮下注100mgシリンジ（一般名：デペモキマブ（遺伝子組換え））における以下2つの適応について、製造販売承認を取得したことをお知らせし","url":"/ja-jp/news/press-releases/20251222-exdensur/","datePublished":"2025年12月22日","dateTime":"2025-12-22T16:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["日本"],"tags":[]},{"headline":"GSKとViiV、LGBTQ+の取り組みを評価する「PRIDE指標2025」、7年連続で最高評価の「ゴールド」認定を獲得","description":"GSKグループの日本法人、グラクソ・スミスクライン株式会社（本社：東京都港区、代表取締役社長：ポール・リレット、以下GSK）と、ヴィーブヘルスケア株式会社（本社：東京都港区、代表取締役社長：村木 基、以下ViiV）は、職場におけるLGBTQ+に関する取組みの評価指標であるPRID","url":"/ja-jp/news/press-releases/20251117-pride_gold/","datePublished":"2025年11月17日","dateTime":"2025-11-17T10:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["日本"],"tags":[]},{"headline":"2025年第3四半期　GSK、第3四半期業績も引き続き好調な業績を達成、2025年のガイダンスを上方修正へ","description":"スペシャリティ医薬品、ワクチン、ジェネラル医薬品が売上高、営業利益、1株あたり利益の成長を牽引","url":"/ja-jp/news/press-releases/20251110_q3-2025/","datePublished":"2025年11月10日","dateTime":"2025-11-10T13:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["グローバル"],"tags":[]},{"headline":"GSKの次期CEOにルーク・マイルズを任命","description":"GSK（本社：英国）は、ルーク・マイルズがGSKの次期最高経営責任者（CEO）に任命されたことを発表しました。2026年1月1日にCEOに就任し取締役会に加わります。","url":"/ja-jp/news/press-releases/20251006-luke-miels-appointed-ceo-designate-for-gsk/","datePublished":"2025年10月6日","dateTime":"2025-10-06T14:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["グローバル"],"tags":[]},{"headline":"GSK、今後5年間で米国の研究開発と製造に300億ドルを投資へ","description":"GSK（本社：英国）は本日、米国における研究開発とサプライチェーンのインフラへ今後5年間で300億ドルを投資する計画を発表しました。","url":"/ja-jp/news/press-releases/20250929-gsk-to-invest-30-billion-in-rd-and-manufacturing-in-the-united-states-over-next-5-years/","datePublished":"2025年9月29日","dateTime":"2025-09-29T14:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["グローバル"],"tags":[]},{"headline":"グラクソ・スミスクライン株式会社 取締役人事についてのお知らせ","description":"グラクソ・スミスクライン株式会社（本社：東京都港区、代表取締役社長：ポール・リレット）は取締役人事に関して下記の通りお知らせいたします。","url":"/ja-jp/news/press-releases/20250904-hr/","datePublished":"2025年9月4日","dateTime":"2025-09-04T14:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["日本"],"tags":[]},{"headline":"GSKのゲポチダシン、単純性淋菌感染症の経口治療薬としての承認申請が、米国FDAの優先審査として受理","description":"GSK（本社：英国）は、12歳以上（45kg以上）の単純性淋菌感染症（淋病）の患者さんにおける経口治療の選択肢を提供するゲポチダシンの適応追加申請について、米国食品医薬品局（FDA）に優先審査として受理されたことをお知らせします。","url":"/ja-jp/news/press-releases/20250827-gepotidacin-accepted-for-priority-review-by-the-us-fda-for-the-oral-treatment-of-uncomplicated-urogenital-gonorrhoea/","datePublished":"2025年8月27日","dateTime":"2025-08-27T15:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["グローバル"],"tags":[]},{"headline":"GSK、2025年第2四半期業績　引き続き好調な業績を達成","description":"スペシャリティ医薬品の好調な業績が、売上高とコア営業利益の成長を牽引","url":"/ja-jp/news/press-releases/20250808_q2-2025/","datePublished":"2025年8月8日","dateTime":"2025-08-08T14:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["グローバル"],"tags":[]},{"headline":"グラクソ・スミスクライン株式会社 取締役人事についてのお知らせ","description":"グラクソ・スミスクライン株式会社（本社：東京都港区、代表取締役社長：ポール・リレット）は取締役人事に関して下記の通りお知らせいたします。","url":"/ja-jp/news/press-releases/20250801-hr/","datePublished":"2025年8月1日","dateTime":"2025-08-01T10:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["日本"],"tags":[]},{"headline":"GSK、再発又は難治性の多発性骨髄腫に対するブーレンレップの併用療法について、EUでの承認を取得","description":"GSK（本社：英国）は、欧州連合（European Union：EU）において、少なくとも1ライン以上の治療歴を有する多発性骨髄腫の成人患者さんに対する、ボルテゾミブおよびデキサメタゾンとの併用療法（BelaVd療法）、および、1ライン以上の治療歴（レナリドミドを含む治療を含む*","url":"/ja-jp/news/press-releases/20250731-blenrep-belantamab-mafodotin-combinations-approved-in-eu-for-treatment-of-relapsedrefractory-multiple-myeloma/","datePublished":"2025年7月31日","dateTime":"2025-07-31T15:00:00","downloadUrl":null,"downloadAriaLabel":null,"downloadFileSize":null,"downloadExtension":null,"categories":["グローバル"],"tags":[]}]},"captions":{"showMore":null,"mostRecent":"新しい順","mostRelevant":"関連性順","search":"Search","download":"Download","resetSearch":"Reset search","clear":"Clear all","noResults":"申し訳ありません。ご希望の条件に合う検索結果が見つかりませんでした。","resultsAvailable":null,"cancel":"Cancel","apply":"Apply","nowPlaying":null,"paginationAriaLabel":"Pagination","previous":"","previousAriaLabel":"Go to previous page","next":"","nextAriaLabel":"Go to next page","goToPageAriaLabel":"Go to page ##PAGE##","currentPageAriaLabel":"Page","numberOfResultsPerPage":"表示件数","playVideo":"Play video {title}","filterBy":"Filter By:","sortBy":"Sort By:","select":"Select","category":"カテゴリー","dateRange":"Select date range","dateRangeBubbleText":"Date range","all":"All","lastWeek":"Last week","lastMonth":"Last month","lastSix":"Last 6 months","searchPrompt":"検索する","resultsText":"{filteredCount} out of {totalCount} results","tabbedArchivedSearchLabel":"","tabbedSearchBarLatestLabel":"","tabbedLatestTabDescription":"","tabbedVersionArchivedDescription":""},"id":3058,"docCheckLogout":null,"pageType":"pressReleaseListingPage","languageCode":"ja-JP","theme":"light","breadcrumb":{"ariaLabel":"Breadcrumbs","links":[{"text":"Home","href":"/ja-jp/","openInNewWindowText":null},{"text":"ニュース","href":"/ja-jp/news/","openInNewWindowText":null},{"text":"報道関係の皆さま向けのお知らせ（プレスリリース）","href":"/ja-jp/news/press-releases/","openInNewWindowText":null}]},"pageName":"報道関係の皆さま向けのお知らせ（プレスリリース）","topNav":{"homeLink":{"text":"GSK Homepage","href":"/ja-jp/","openInNewWindowText":null},"topBar":{"currentLocation":{"isGlobal":false,"text":"Japan (JP)"},"languageSelector":{"currentLanguage":null,"currentLanguageMobile":null,"selectableLanguages":[]},"darkModeSwitch":{"text":"ダークモード","tooltipText":"

ダークモードに切り替えて、より持続可能な世界を一緒に目指しましょう。詳細はこちら

"},"globalSiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},"locationSelector":{"text":"Location selector","href":"/ja-jp/locations/","openInNewWindowText":null},"healthCareLink":{"text":"医療関係者向け情報","href":"https://gskpro.com/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},"contactUs":{"text":"お問い合わせ","href":"/ja-jp/contact-us/","openInNewWindowText":null},"search":"検索する","backToMain":"Back to main","menu":"Menu","closeMenu":"閉じる","animationsToggleModel":{"enable":true,"activeText":"ビデオを一時停止する","inactiveText":"ビデオを再生する"}},"nodes":[{"tooltip":null,"hasBorderRight":false,"title":"GSKについて","url":"/ja-jp/company/","nodes":[{"title":"存在意義・戦略・カルチャー","url":"/ja-jp/company/purpose-strategy-and-culture/","nodes":[],"isActive":false},{"title":"日本法人 会社概要","url":"/ja-jp/company/at-a-glance/","nodes":[{"title":"今市工場～適切な品質の医薬品を確実にお届けする","url":"/ja-jp/company/at-a-glance/about-imaichi-factory/","nodes":[],"isActive":false}],"isActive":false},{"title":"日本法人社長メッセージ","url":"/ja-jp/company/president-message/","nodes":[],"isActive":false},{"title":"行動指針","url":"/ja-jp/company/policies-codes-and-standards/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"存在意義・戦略・カルチャー","image":{"src":"/media/psrlzurd/gsk_tech_human_image_6k_30056.png?width=329&height=185&format=webp&quality=100&v=1dc0141891810b0&hmac=c3d3b0dc9c0698cb6e4d5ca0017f4bcc00a1d23ce5e5ef30fc1b645826af0102","alt":"存在意義・戦略・カルチャー","darkModeSrc":"/media/psrlzurd/gsk_tech_human_image_6k_30056.png?width=329&height=185&format=webp&quality=90&v=1dc0141891810b0&hmac=4b39810dec847f5508e1335d35b6161b76af966eea09508d17a428f3990b318e"},"link":{"text":"FEATURED SECTION","href":"/ja-jp/company/purpose-strategy-and-culture/","openInNewWindowText":null}},{"text":"採用情報","image":{"src":"/media/nnqgbuwz/_s3a0516_600x337.jpg?width=329&height=185&format=webp&quality=100&v=1dc0141e3b9aa10&hmac=71df43901f99cc0f3c20f2ac788bc1f75b79ea5e4022eee9456ed681e01aece0","alt":"採用情報","darkModeSrc":"/media/nnqgbuwz/_s3a0516_600x337.jpg?width=329&height=185&format=webp&quality=90&v=1dc0141e3b9aa10&hmac=a5c64494edbaaf0743019464a48116bef41308be6cec33adfe25f4f6c2b9b4d5"},"link":{"text":"SPOTLIGHT ON","href":"/ja-jp/careers/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"イノベーション","url":"/ja-jp/innovation/","nodes":[{"title":"疾患領域","url":"/ja-jp/innovation/therapeutic-areas/","nodes":[{"title":"呼吸器・免疫・炎症","url":"/ja-jp/innovation/therapeutic-areas/respiratory-immunology-and-inflammation/","nodes":[],"isActive":false},{"title":"オンコロジー","url":"/ja-jp/innovation/therapeutic-areas/oncology/","nodes":[],"isActive":false},{"title":"HIV","url":"/ja-jp/innovation/therapeutic-areas/hiv/","nodes":[],"isActive":false},{"title":"感染症","url":"/ja-jp/innovation/therapeutic-areas/infectious-diseases/","nodes":[],"isActive":false}],"isActive":false},{"title":"開発パイプライン","url":"/ja-jp/innovation/pipeline/","nodes":[],"isActive":false},{"title":"臨床試験","url":"/ja-jp/innovation/trials-in-people/","nodes":[{"title":"臨床試験とは","url":"/ja-jp/innovation/trials-in-people/about-trials-in-people/","nodes":[],"isActive":false},{"title":"治験結果","url":"/ja-jp/innovation/trials-in-people/simple-trial-data/","nodes":[],"isActive":false},{"title":"治験情報 免責事項","url":"/ja-jp/innovation/trials-in-people/clinical-trial-information-notice/","nodes":[],"isActive":false},{"title":"データ二次利用による臨床研究の公開","url":"/ja-jp/innovation/trials-in-people/clinical-trials-optout/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"開発パイプライン","image":{"src":"/media/xebp324o/ware_3_2022_prodqc_14_hess.jpg?width=329&height=185&format=webp&quality=100&v=1dc01418c117a90&hmac=c3f70382a3c6ba6bb65420900da197ea23631e2ce4a7d67ead94c26abb5bf4af","alt":"開発パイプライン","darkModeSrc":"/media/xebp324o/ware_3_2022_prodqc_14_hess.jpg?width=329&height=185&format=webp&quality=90&v=1dc01418c117a90&hmac=24a8c7f44cbc8d4190e0d56ce2ed0adb61a0196e315650c59063e125c3f8ba1b"},"link":{"text":"FEATURED SECTION","href":"/ja-jp/innovation/pipeline/","openInNewWindowText":null}},{"text":"Global Innovation","image":{"src":"/media/pscnepnu/data-and-dna-image.jpg?width=329&height=185&format=webp&quality=100&v=1dce0f7b6a4cd70&hmac=df563d640fcc53763c5e8e380125c11b6abf689c7baa6c33e831d7cd6d0040f2","alt":"Global Innovation","darkModeSrc":"/media/pscnepnu/data-and-dna-image.jpg?width=329&height=185&format=webp&quality=90&v=1dce0f7b6a4cd70&hmac=e3df89150dd078346ba3ea5dea99fe99b7df2dfba66aeeeb282f431bae314a56"},"link":{"text":"SPOTLIGHT ON","href":"https://www.gsk.com/en-gb/innovation/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"}}]},{"tooltip":null,"hasBorderRight":false,"title":"製品情報","url":"/ja-jp/products/","nodes":[{"title":"医療用医薬品（患者さま向けくすりの情報）","url":"/ja-jp/products/our-prescription-medicines/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"イノベーション","image":{"src":"/media/qtbfhkic/otsuki-san.jpg?width=329&height=185&format=webp&quality=100&v=1dc01418c60d310&hmac=b169a7206261e607e0fed4b3f7125ce2e57df94353fc4817fa78951ecd3bcffa","alt":"イノベーション","darkModeSrc":"/media/qtbfhkic/otsuki-san.jpg?width=329&height=185&format=webp&quality=90&v=1dc01418c60d310&hmac=d0a068bd7fc5c3459a238f9f7f73c2dc2ed17d0bee0bab62ef85aa0c88c56ebe"},"link":{"text":"SPOTLIGHT ON","href":"/ja-jp/innovation/","openInNewWindowText":null}},{"text":"医療関係の皆さま向けサイト","image":{"src":"/media/s0npmulr/navthumb_stvg_03_2022_port_32_eagle_orange-1_mnav.jpg?width=329&height=185&format=webp&quality=100&v=1dc01418e842840&hmac=38c2d6c1e39a451e7db216b916e16b9562287f6ba9aa7e5ff80986051cef1809","alt":"医療関係の皆さま向けサイト","darkModeSrc":"/media/s0npmulr/navthumb_stvg_03_2022_port_32_eagle_orange-1_mnav.jpg?width=329&height=185&format=webp&quality=90&v=1dc01418e842840&hmac=6f46a5901b98bf9cbe28a5676450935352d23d555390fd3d63dd809fc77c4f25"},"link":{"text":"FEATURED WEBSITE","href":"https://gskpro.com/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"}}]},{"tooltip":null,"hasBorderRight":true,"title":"企業責任","url":"/ja-jp/responsibility/","nodes":[{"title":"アクセス","url":"/ja-jp/responsibility/access/","nodes":[],"isActive":false},{"title":"グローバルへルスとヘルスセキュリティ","url":"/ja-jp/responsibility/global-health-and-health-security/","nodes":[],"isActive":false},{"title":"環境","url":"/ja-jp/responsibility/environment/","nodes":[],"isActive":false},{"title":"インクルージョン ","url":"/ja-jp/responsibility/inclusion/","nodes":[{"title":"日本におけるLGBTQ＋に対する取り組み","url":"/ja-jp/responsibility/inclusion/lgbtqplus/","nodes":[],"isActive":false}],"isActive":false},{"title":"倫理基準","url":"/ja-jp/responsibility/ethical-standards/","nodes":[{"title":"医療機関及び医療関係者との関係の透明性","url":"/ja-jp/responsibility/ethical-standards/transparency-hcps/","nodes":[],"isActive":false},{"title":"患者団体との関係の透明性","url":"/ja-jp/responsibility/ethical-standards/transparency-patient-groups/","nodes":[],"isActive":false},{"title":"贈収賄防止への取り組み","url":"/ja-jp/responsibility/ethical-standards/efforts-to-bribery-prevention/","nodes":[],"isActive":false}],"isActive":false},{"title":"製品ガバナンス","url":"/ja-jp/responsibility/product-governance/","nodes":[],"isActive":false},{"title":"医学・薬学に関連する団体や患者団体への支援","url":"/ja-jp/responsibility/grants-donations/","nodes":[],"isActive":false},{"title":"GSK医学教育事業助成","url":"/ja-jp/responsibility/ime-grant/","nodes":[],"isActive":false},{"title":"患者団体との協働","url":"/ja-jp/responsibility/our-support/","nodes":[],"isActive":false},{"title":"新型インフルエンザへの対応","url":"/ja-jp/responsibility/influenza/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"インクルージョン","image":{"src":"/media/xj0ln5vy/s3a1341_600x350.jpg?width=329&height=185&format=webp&quality=100&v=1dce1c17bf2f510&hmac=8112879cd3b6f2790141650a0b3c0bfbb2dfd8c4be4a1616af09af5419077902","alt":"インクルージョン","darkModeSrc":"/media/xj0ln5vy/s3a1341_600x350.jpg?width=329&height=185&format=webp&quality=90&v=1dce1c17bf2f510&hmac=26bdd6ee26c639e58f240a12018b05e406b95bb5a146559f1872448ddc8882b8"},"link":{"text":"FEATURED SECTION","href":"/ja-jp/responsibility/inclusion/","openInNewWindowText":null}},{"text":"行動指針","image":{"src":"/media/f5rg2rd1/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dc014185d800e0&hmac=b99ced4ba2316d27c3db9b99c4e8813e0289baff18bc68b8c5cfaa8c707cb059","alt":"行動指針","darkModeSrc":"/media/f5rg2rd1/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=90&v=1dc014185d800e0&hmac=130304d22336c72d93cfb2e988301b9e69aec1859b99d51357b11e4fabf0c6e1"},"link":{"text":"SPOTLIGHT ON","href":"/ja-jp/company/policies-codes-and-standards/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"ニュース","url":"/ja-jp/news/","nodes":[{"title":"報道関係の皆さま向けのお知らせ（プレスリリース）","url":"/ja-jp/news/press-releases/","nodes":[],"isActive":true},{"title":"報道関係の皆さま向けのお問い合わせ","url":"/ja-jp/news/media-contacts/","nodes":[],"isActive":false},{"title":"医療関係の皆さまへのお知らせ","url":"/ja-jp/news/healthcare-professionals/","nodes":[],"isActive":false},{"title":"一般・患者の皆さまのへお知らせ","url":"/ja-jp/news/consumers/","nodes":[],"isActive":false},{"title":"その他のお知らせ","url":"/ja-jp/news/responsibility-news/","nodes":[],"isActive":false},{"title":"注目の取り組み","url":"/ja-jp/news/in-focus/","nodes":[{"title":"疾患情報サイト（患者さま向け）","url":"/ja-jp/news/in-focus/disease-information/","nodes":[],"isActive":false}],"isActive":false},{"title":"私たちのソーシャルメディア","url":"/ja-jp/news/our-social-media/","nodes":[],"isActive":false}],"isActive":true,"promos":[{"text":"疾患情報サイト（患者さま向け）","image":{"src":"/media/xmdfpoex/disease-information_navi.jpg?width=329&height=185&format=webp&quality=100&v=1dc0141d77b8250&hmac=06f41e2e63eb6eba42c22ec0d444aa53340afdfc38eac839382015e1a0e66d6f","alt":"疾患情報サイト（患者さま向け）","darkModeSrc":"/media/xmdfpoex/disease-information_navi.jpg?width=329&height=185&format=webp&quality=90&v=1dc0141d77b8250&hmac=a709c211c21f79f933dfa49cdf23189dc9bc060b50c8d8709182ef80a428aed8"},"link":{"text":"FEATURED SECTION","href":"/ja-jp/news/in-focus/disease-information/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"採用情報","url":"/ja-jp/careers/","nodes":[{"title":"Life at GSK – GSKで働く","url":"/ja-jp/careers/life-at-gsk/","nodes":[{"title":"社員の能力開発","url":"/ja-jp/careers/life-at-gsk/developing-our-people/","nodes":[],"isActive":false},{"title":"社員の健康、安全および福利","url":"/ja-jp/careers/life-at-gsk/emploee-health-safety-and-well-being/","nodes":[],"isActive":false},{"title":"パフォーマンスに対する報酬","url":"/ja-jp/careers/life-at-gsk/rewarding-performance/","nodes":[],"isActive":false},{"title":"人事制度のご案内","url":"/ja-jp/careers/life-at-gsk/personnel-system/","nodes":[],"isActive":false}],"isActive":false},{"title":"中途採用","url":"/ja-jp/careers/experienced-professionals/","nodes":[],"isActive":false},{"title":"募集職種・エントリー","url":"/ja-jp/careers/recruitment/","nodes":[],"isActive":false},{"title":"人財本部長からのメッセージ","url":"/ja-jp/careers/message/","nodes":[],"isActive":false},{"title":"社員の声","url":"/ja-jp/careers/our-people-interview/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"社員の声","image":{"src":"/media/cr1piyay/interview_navi.jpg?rxy=0.48166666666666669,0.35207100591715978&width=329&height=185&format=webp&quality=100&v=1dc0141e83a9e50&hmac=92181227f877b4fd1f0e790afb5f3e04cabc371b2982fcc9a08fec2786512fa3","alt":"社員の声","darkModeSrc":"/media/cr1piyay/interview_navi.jpg?rxy=0.48166666666666669,0.35207100591715978&width=329&height=185&format=webp&quality=90&v=1dc0141e83a9e50&hmac=1e3378bec649d61cee76f3c8460cc2d8e8b2c1fdcd39eff9c266bc14f812345f"},"link":{"text":"FEATURED SECTION","href":"/ja-jp/careers/our-people-interview/","openInNewWindowText":null}}]}],"skipToContent":null,"skipToSearch":null,"typeaheadSearch":{"apiEndpoint":"api/search/typeahead?siteContainerId=1703","searchFieldPlaceholderText":"検索する","searchPage":"/ja-jp/search/","ariaLabel":"Submit form"},"ariaLabel":"Global navigation"},"footer":{"logo":null,"copyrightText":"

当サイトに掲載されている情報は日本国内に居住
されている方のためのもので、日本の事業に関す
る情報を求める方を対象とした日本のウェブサイ
トです。
GSKグローバルサイト（英語）はLocation selectorからアクセスいただけます。

\n

© 2001-2026 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.

\n

GSK plc. Registered in England and Wales No. 3888792.

\n

グラクソ・スミスクライン株式会社
東京都港区赤坂1-8-1 赤坂インターシティAIR

","modernSlaveryStatement":null,"sections":{"socialMedia":{"columnTitle":"Follow us on:","socialMediaItems":[{"globalLink":{"text":"Global","href":"https://www.instagram.com/gsk/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},"localLink":{"text":"日本","href":"https://www.instagram.com/gsk_japan/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},"ariaLabel":"Follow us on Instagram","customIcon":null,"showPopupMenu":false,"type":"Instagram"},{"globalLink":{"text":"Global","href":"https://www.facebook.com/GSK","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},"localLink":{"text":"日本","href":"https://www.facebook.com/glaxosmithkline.japan/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},"ariaLabel":"Follow us on Facebook","customIcon":null,"showPopupMenu":false,"type":"Facebook"},{"globalLink":{"text":null,"href":"https://twitter.com/GSK","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on X","customIcon":null,"showPopupMenu":false,"type":"X"},{"globalLink":{"text":null,"href":"https://www.youtube.com/GSK","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on Youtube","customIcon":null,"showPopupMenu":false,"type":"Youtube"},{"globalLink":{"text":null,"href":"http://www.linkedin.com/company/glaxosmithkline","openInNewWindowText":null},"localLink":null,"ariaLabel":"Follow us on LinkedIn","customIcon":null,"showPopupMenu":false,"type":"LinkedIn"}]},"columns":[{"columnTitle":"GSKのウェブサイト","links":[{"text":"GSKグローバルサイト（英語）","href":"https://www.gsk.com/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},{"text":"世界のGSKサイト","href":"/ja-jp/locations/","openInNewWindowText":null},{"text":"Global Behind the science","href":"https://www.gsk.com/en-gb/behind-the-science/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},{"text":"医療関係の皆さま","href":"https://gskpro.com/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},{"text":"ヴィーブヘルスケア株式会社","href":"https://viivhealthcare.com/ja-jp/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},{"text":"薬剤師の皆さま","href":"https://gskpro.com/ja-jp/yakuzaishi/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},{"text":"Supplier website","href":"https://supplier.gsk.com/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"}]},{"columnTitle":"クイックリンク","links":[{"text":"GSKについて","href":"/ja-jp/company/","openInNewWindowText":null},{"text":"イノベーション","href":"/ja-jp/innovation/","openInNewWindowText":null},{"text":"製品情報","href":"/ja-jp/products/","openInNewWindowText":null},{"text":"企業責任","href":"/ja-jp/responsibility/","openInNewWindowText":null},{"text":"ニュース","href":"/ja-jp/news/","openInNewWindowText":null},{"text":"採用情報","href":"/ja-jp/careers/","openInNewWindowText":null}]},{"columnTitle":"お問い合わせ","links":[{"text":"お問い合わせ","href":"/ja-jp/contact-us/","openInNewWindowText":null},{"text":"副作用/副反応のご報告","href":"https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=sideeffect&ref=vaccine","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},{"text":"GSK Speak up","href":"https://gsk.i-sight.com/landing-page/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"}]}]},"bottomLinks":[{"text":"アクセシビリティ","href":"/ja-jp/accessibility/","target":"_parent","openInNewWindowText":"新しいウィンドウで開く"},{"text":"デジタル・サステナビリティ","href":"/ja-jp/digital-sustainability/","openInNewWindowText":null},{"text":"ご利用条件","href":"/ja-jp/terms-of-use/","target":"_parent","openInNewWindowText":"新しいウィンドウで開く"},{"text":"クッキーポリシー","href":"/ja-jp/cookie-policy/","target":"_parent","openInNewWindowText":"新しいウィンドウで開く"},{"text":"プライバシー通知","href":"https://privacy.gsk.com/ja-jp/privacy-notice/general/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},{"text":"サイトマップ","href":"/ja-jp/sitemap/","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"}],"continueToLink":null,"legalApprovalText":""},"sharing":{"description":"GSKの最新および過去のプレスリリースがご覧になれます。","og":[{"property":"og:title","content":"報道関係の皆さま向けのお知らせ（プレスリリース）"},{"property":"og:description","content":"GSKの最新および過去のプレスリリースがご覧になれます。"},{"property":"og:image","content":"https://jp.gsk.com/media/20ppkxwb/gsk_logo_full_colour_rgb.png?width=600&format=webp&quality=100&v=1dc0141fb310cb0&hmac=28fb0b041a15f4949dc0fe35d9f219d99a5d492e36cb60073f0cb1574199712c"},{"property":"og:url","content":"https://jp.gsk.com/ja-jp/news/press-releases/"}],"twitter":[{"name":"twitter:card","content":"summary_large_image"},{"name":"twitter:site","content":"@gsk"},{"name":"twitter:title","content":"報道関係の皆さま向けのお知らせ（プレスリリース）"},{"name":"twitter:description","content":"GSKの最新および過去のプレスリリースがご覧になれます。"},{"name":"twitter:image","content":"https://jp.gsk.com/media/20ppkxwb/gsk_logo_full_colour_rgb.png?width=600&format=webp&quality=100&v=1dc0141fb310cb0&hmac=28fb0b041a15f4949dc0fe35d9f219d99a5d492e36cb60073f0cb1574199712c"},{"name":"twitter:url","content":"https://jp.gsk.com/ja-jp/news/press-releases"}]},"stickyShare":null,"exitSitePreferences":{"popupEnabled":true,"title":"","texts":"

これからアクセスしようとしているウェブサイトの内容は、グラクソ・スミスクライン株式会社によって管理されているものではありません。その正確性、安全性、信頼性はグラクソ・スミスクライン株式会社が保証しているものではないことをご了承ください。

","continueText":"続ける","cancelText":"戻る","exclusionUrls":["https://jp.gsk.com","https://jp.gsk.com/","https://gskpro.com/","https://gskpro.com/ja-jp/","https://gskpro.com/ja-jp/yakuzaishi/","https://kusurigsk.jp/","http://kusurigsk.jp/","https://glaxosmithkline.co.jp/","https://glaxosmithkline.co.jp/gsk-chj/","https://glaxosmithkline.co.jp/gsk-chj/products/","https://glaxosmithkline.co.jp/gsk-chj/contact-us/dental-care/","https://glaxosmithkline.co.jp/gsk-chj/contact-us/nonprescription/","https://glaxosmithkline.co.jp/legal/inquire3_1.html","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=medicine1&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=medicine2&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=sideeffect&ref=vaccine","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=research&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=recruit&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=media&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=privacy&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=compliance&ref=GSKCorporate","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=other&ref=GSKCorporate","https://glaxosmithkline.co.jp/viiv/index.html","https://glaxosmithkline.co.jp/crsf/healthcare/","https://jobs.gsk.com/ja-jp/jobs","https://youtu.be/z5bVnkcBEQo?rel=0","https://www.facebook.com/glaxosmithkline.japan/","https://privacy.gsk.com/ja-jp/privacy-notice/general/","https://btx-a.jp/kao/","https://btx-a.jp/kubi/","https://btx-a.jp/shoni/","http://keishuku.jp/","http://waki-ase.jp/","https://pah.jp/","https://hainyo-onayami.jp/","http://jp.gsk.com/","http://lovesbaby.jp/","https://taijouhoushin-yobou.jp/","http://allwomen.jp/","https://www.broughtbyvaccines.com/ja-jp/","https://jpv5.staging.gsk.com/#market-selector","https://jp.gsk.com/ja-jp/#market-selector","https://kusurigsk.jp/aaa/","https://kusurigsk.jp/aa/","https://kusurigsk.jp/al/","https://kusurigsk.jp/sul/","https://kusurigsk.jp/sere/","https://kusurigsk.jp/sered/","https://kusurigsk.jp/ft/","https://kusurigsk.jp/ftd/","https://kusurigsk.jp/fta/","https://gskpro.com/ja-jp/products-info/relenza/","https://keiren.jp/","https://shakei.jp/","https://shoni.jp/","https://acsprtnavi.c-nuage.jp/~gsk_rg/as/application/toppage","https://acsprtnavi.c-nuage.jp/~gsk/as/application/toppage","https://taijouhoushin-yobou.jp/?utm_source=pr&utm_medium=press_release&utm_campaign=gsk","https://www.broughtbyvaccines.com/ja-jp/?utm_source=pr&utm_medium=press_release&utm_campaign=gsk","https://broughtbyvaccines.com/ja-jp/","https://glaxosmithkline.co.jp/corp/compliance/view/","https://glaxosmithkline.co.jp/corp/compliance/view/index2019.html","https://glaxosmithkline.co.jp/corp/compliance/view/agree_advance.php?t=T-SEARCH","https://glaxosmithkline.co.jp/corp/compliance/patient/agree.html","https://allwomen.jp/","https://www.gskhealthpartner.com/ja-jp/oral-health/","https://glaxosmithkline.co.jp/corp/compliance/view/index2020.html","https://privacy.gsk.com/ja-jp/privacy-notice/","http://www.gsk.com","https://www.gsk.com","https://www.gsk.com/","https://www.gsk.com/en-gb/behind-the-science/","https://supplier.gsk.com/irj/portal/public","https://gsk.i-sight.com/landing-page/","https://www.gsk.com/en-gb/innovation/research-and-development-approach/","https://www.gsk.com/en-gb/innovation/partnerships/","https://www.gsk.com/media/7473/esg-performance-report-2021.pdf","https://www.gsk.com/media/8519/the-code-printable-version.pdf","https://www.gsk.com/media/8518/policies-and-standards.pdf","https://www.gsk.com/en-gb/company/gsk-at-a-glance/","https://www.gsk.com/media/8519/the-code-printable-version.pdf","https://www.gsk.com/media/8518/policies-and-standards.pdf","https://www.gsk.com/media/9281/gsk-position-on-working-with-third-parties-december-2019.pdf","https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/binding-corporate-rules/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/","https://www.gsk.com/en-gb/innovation/pipeline/","https://www.gsk.com/en-gb/research-and-development/trials-in-people/gsk-study-register-and-patient-level-data/","https://www.gsk.com/en-gb/products/our-product-areas/","https://www.gsk.com/en-gb/responsibility/pricing-and-access/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/","https://www.gsk.com/en-gb/responsibility/environmental-sustainability/","https://www.gsk.com/en-gb/responsibility/product-governance/","https://us.gsk.com/en-us/about-us/us-community-partnerships/stem-education/philadelphia-stem-equity-collective/","https://www.gsk.com/en-gb/responsibility/charitable-partnerships/","https://www.gsk.com/en-gb/company/governance/compliance/","https://www.gsk.com/en-gb/responsibility/ethical-standards/","https://www.gsk.com/en-gb/responsibility/ethical-standards/working-with-third-parties/","https://www.gsk.com/en-gb/responsibility/ethical-standards/public-policy-and-patient-advocacy/","https://www.gsk.com/en-gb/responsibility/ethical-standards/human-rights/","https://www.gsk.com/en-gb/responsibility/ethical-standards/use-of-animals/","https://www.gsk.com/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/","https://www.gsk.com/en-gb/responsibility/operating-responsibly/ethics-and-values/","https://www.gsk.com/en-gb/careers/","https://www.gsk.com/en-gb/innovation/","https://www.gsk.com/media/9632/q3-2022-results-announcement.pdf","https://www.gsk.com/en-gb/media/press-releases/us-food-and-drug-administration-accepts-new-drug-application-for-daprodustat/","https://www.gsk.com/en-gb/media/press-releases/gsk-receives-first-regulatory-approval-for-duvroq-daprodustat-in-japan-for-patients-with-anaemia-due-to-chronic-kidney-disease/","https://www.gsk.com/media/9384/understanding-our-value-chain-carbon-footprint.pdf","https://www.gsk.com/media/9374/understanding-our-value-chain-water-footprint.pdf","https://www.gsk.com/en-gb/responsibility/environmental-sustainability/biodiversity/","https://www.gsk.com/media/9386/q2-2022-results-announcement.pdf","https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Sotrovimab/pdf/SOTROVIMAB-EUA.PDF#nameddest=HCPFS","https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Sotrovimab/pdf/SOTROVIMAB-PATIENT-FACT-SHEET.PDF","https://www.ema.europa.eu/en/news/ema-issues-advice-use-sotrovimab-vir-7831-treating-covid-19","https://www.gsk.com/en-gb/media/press-releases/ema-issues-positive-scientific-opinion-on-gsk-and-vir-biotechnology-s-sotrovimab-for-the-early-treatment-of-covid-19/","https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-sotrovimab-vir-7831-receives-emergency-use-authorization-from-the-us-fda/","https://www.gsk.com/en-gb/about-us/","https://gskpro.com/content/dam/global/hcpportal/ja_JP/products-info/nucala/nucala.pdf","https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF","https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tre%20legy/pdf/TRELEGY-PI-MG-IFU.PDF","https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL.PDF","https://www.gsk-clinicalstudyregister.com/study/116855?search=study&search_terms=FF%2FUMEC%2FVI%2B&ps","https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Trelegy/pdf/TRELEGY-PI-MG-IFU.PDF","https://www.gsksource.com/pharma/content/gsk/source/us/en/brands/nucala/pi/saep.html","https://livlife.com/jp-jp/","https://gskpro.com/ja-jp/products-info/lamictal-epi/adult-dosage/","https://gskpro.com/ja-jp/products-info/lamictal-bp/dosage/","https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Breo_Ellipta/pdf/BREO-ELLIPTA-PI-MG.PDF","http://jp.gsk.com","http://jp.gsk.com/","http://www.gsk.com/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/infectious-diseases/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/hiv/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/oncology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/immunology/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/opportunity-driven/","https://viivhealthcare.com/","https://www.youtube.com/embed/zqwxYjuEtaY","https://www.youtube.com/watch?v=ibGWPULYxdM","https://www.facebook.com/GSK","https://twitter.com/GSK","https://www.youtube.com/GSK","http://www.linkedin.com/company/glaxosmithkline","https://www.instagram.com/gsk/","https://www.gsk.com/en-gb/innovation/technologies/","https://www.gsk.com/en-gb/innovation/rd-locations/","https://www.gsk.com/en-gb/media/our-response-to-covid-19/","https://www.gsk.com/speakup","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=donation&ref=GSKCorporate","https://medical.gsk.com/ja-jp/","https://www.egpa.jp/","https://www.gsk.com/en-gb/responsibility/esg-resources/","https://www.gsk.com/en-gb/innovation/therapeutic-areas/immunologyrespiratory/","https://www.gsk.com/media/10013/q1-2023-results-announcement.pdf","https://viivhealthcare.com/ja-jp/","https://www.gsk.com/media/10423/q2-2023-results-announcement.pdf","https://glaxosmithkline.co.jp/corp/compliance/view/index2021.html","https://www.zensoku.jp/","https://lin.ee/674pSLG","https://www.gsk.com/en-gb/media/press-releases/gsk-and-viiv-healthcare-to-present-scientific-advancements-at-idweek-2023/","https://www.gsk-savethechildren.com/","https://rsvirus.jp/","https://www.gsk.com/media/10667/q3-2023_31-october_final.pdf","https://zensoku.jp/","https://youtu.be/DzEwmhXsaRE","https://www.gsk.com/media/10928/fy-2023-results-announcement.pdf","https://www.gsk.com/media/9281/position-on-working-with-third-parties-2023.pdf","https://with-sle.jp/","https://www.gsk.com/en-gb/media/press-releases/dreamm-7-phase-iii-trial-shows-pfs-improvement-and-strong-os-trend-for-blenrep-combo-versus-soc-combo-in-multiple-myeloma/","https://www.gsk.com/en-gb/investors/quarterly-results/","https://www.gsk.com/media/11099/q1-2024-results-announcement.pdf","https://www.gsk.com/en-gb/media/press-releases/positive-ruby-phase-iii-data-show-potential-for-jemperli-dostarlimab-combinations-in-more-patients-with-primary-advanced-or-recurrent-endometrial-cancer/","https://www.gsk.com/en-gb/media/press-releases/blenrep-combination-reduced-the-risk-of-disease-progression/","https://www.gsk.com/media/11412/q2-2024-results-announcement.pdf","https://glaxosmithkline.co.jp/corp/compliance/view/index2022.html","https://youtu.be/qNK8ftLE8F8","https://youtu.be/_DJW9Rg5o-M","https://www.gsk.com/en-gb/contact-us/","https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b/","https://www.gsk.com/en-gb/responsibility/environment/climate/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/global-health/","https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/health-security/","https://www.gsk.com/en-gb/responsibility/environment/","https://www.gsk.com/en-gb/responsibility/","https://www.gsk.com/media/11646/q3-2024-results-announcement.pdf","https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2023/","https://www.gsk.com/media/11009/esg-performance-report-2023.pdf","https://www.gsk.com/media/10999/environmental-data-2023.pdf","https://www.gsk.com/media/11010/pathway-to-a-net-zero-impact-on-climate.pdf","https://www.gsk.com/media/10534/nature-report-september-2023.pdf","https://www.gsk.com/media/11014/basis-of-reporting-environmental-data-2023.pdf","https://www.gsk.com/en-gb/behind-the-science-magazine/health-equity-gap-medicine-vaccine-access/","https://www.gsk.com/en-gb/innovation/trials/diversity-in-clinical-trials/","https://www.gsk.com/en-gb/responsibility/charitable-investments/","https://www.gsk.com/media/10994/uk-gender-pay-gap-report-2023.pdf","https://www.gsk.com/media/10995/uk-ethnicity-pay-gap-report-2023.pdf","https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-designation-in-china-for-treatment-of-relapsedrefractory-multiple-myeloma/","https://www.gsk.com/en-gb/media/press-releases/us-fda-advisory-committee-votes-in-support-of-trials-designed-to-evaluate-jemperli-dostarlimab-gxly-as-a-potential-treatment-for-dmmrmsi-h-locally-advanced-rectal-cancer/","https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-breakthrough-therapy-designation/","https://www.gsk.com/en-gb/media/press-releases/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093/","https://www.gsk.com/media/11776/fy-2024-results-announcement.pdf","https://www.gsk.com/en-gb/media/press-releases/depemokimab-delivers-clinically-meaningful-and-statistically-significant-improvements-for-patients-with-chronic-rhinosinusitis-with-nasal-polyps-crswnp/","https://www.gsk.com/en-gb/investors/","https://kotsuzui-senisho.jp/","https://www.gsk.com/en-gb/innovation/our-leading-scientists/","https://glaxosmithkline.co.jp/legal/inquire3_1.html?about=sideeffect&ref=GSKpro","https://www.gsk.com/en-gb/media/press-releases/blenrep-combinations-accepted-for-review-by-the-us-fda-for-the-treatment-of-relapsedrefractory-multiple-myeloma/","https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-in-multiple-myeloma-application-accepted-for-review-by-the-european-medicines-agency/","https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-in-relapsedrefractory-multiple-myeloma-accepted-for-regulatory-review-in-japan/","https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combination-accepted-for-priority-review-in-china-in-relapsedrefractory-multiple-myeloma/","https://www.gsk.com/media/11776/fy-2024-results-announcement.pdf","https://www.gsk.com/media/11962/q1-2025-results-announcement.pdf","https://www.gskgrants.com/","https://taijouhoushin-yobou.jp/info-search.html","https://youtu.be/-1PHXPEH298","https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2024/","https://www.gsk.com/en-gb/responsibility/responsibility-reports/","https://www.gsk.com/media/11849/environmental-data-2024.pdf","https://www.instagram.com/gsk_japan/","https://supplier.gsk.com/","https://tahatsusei-kotsuzuishu.jp/","https://toumeisei.jp/view/?id=3035gsh"]},"settings":{"optionalStylesheetLink":"/media/qm1p21vs/optional_style_u13_jp.css","themeColorHexCode":null,"headerLogoLightTheme":null,"headerLogoDarkTheme":null,"footerLogo":{"src":"https://jp.gsk.com/media/3rjfqjwb/gsk-logo.png?width=104&format=webp&quality=100&v=1dc0141fa7adc10&hmac=f1f3775c34588d8b1c06cd105d51babaa8c70fc16360eb72cc9199e33014d081","alt":"GSK Logo","darkModeSrc":"https://jp.gsk.com/media/3rjfqjwb/gsk-logo.png?width=104&format=webp&quality=90&v=1dc0141fa7adc10&hmac=03cc7b702c27067a41b57c2a4e6e12dbdb0e8f7080e30634a5a61e8ef634aab0"},"scripts":[{"pageLocation":"Top","text":" \n"}],"globalWebsiteLink":{"text":"Global","href":"https://www.gsk.com","target":"_blank","openInNewWindowText":"新しいウィンドウで開く"},"googleMapsApiKey":"AIzaSyA2QMg4Ww6djPKb7b9BraQn4kgJmDaLblg","textToSpeechApiKey":"","bingVerificationCode":"","googleAnalytics":"","siteTitle":" | GSK グラクソ･スミスクライン"},"pageSettings":{"disableBackToTopButton":false,"backToTopButtonText":"トップへ戻る","robotsNoFollow":false,"robotsNoIndex":false,"canonicalUrl":"https://jp.gsk.com/ja-jp/news/press-releases/"},"tealiumSettings":{"enabled":false,"data":""},"entryPopup":null,"protectedPage":false,"schema":null,"modules":[{"type":"varied-signpost-grid","title":"こちらもご覧ください","layoutPattern":4,"pages":[{"title":"GSKについて","content":"私たちは、力強い推進力と高い志を持つ専門性の高いバイオ医薬品企業です。","image":{"src":"/media/0anglri2/immuno_oncology_octane_ry_6k_still_1280x720px.jpg?width=427&height=533&format=webp&quality=100&v=1dc014182f5ef90&hmac=82f4ec9860369cb3dbf832e05b24700e4befec84e7b0b242616500266037b2f9","alt":"GSKについて","darkModeSrc":"/media/0anglri2/immuno_oncology_octane_ry_6k_still_1280x720px.jpg?width=427&height=533&format=webp&quality=90&v=1dc014182f5ef90&hmac=86bf0d049b3d79ee5d2ff115c2b36d5bf35fd15de0cd41ced7f9898b7e6c50e0"},"link":{"text":"Company","href":"/ja-jp/company/","openInNewWindowText":null}},{"title":"企業責任","content":"GSKでは、サイエンス、テクノロジー、人財を結集し、力を合わせて病に先手を打つ、という存在意義を事業の指針として掲げています。","image":{"src":"/media/zpafo5ke/202606_responsibility_hero.jpg?rxy=0.4587423312883436,0.6347492328713875&width=427&height=533&format=webp&quality=100&v=1dcfeea78b0d750&hmac=6465c055a67805c17ab2c410bf692d204fecf89baa2acf84c72f096c4ed4efb3","alt":"企業責任","darkModeSrc":"/media/zpafo5ke/202606_responsibility_hero.jpg?rxy=0.4587423312883436,0.6347492328713875&width=427&height=533&format=webp&quality=90&v=1dcfeea78b0d750&hmac=e427a761eb378fd461578364dfc6a892d5ce8c62b760ddfbdb97a4a56b505e0e"},"link":{"text":"Responsibility","href":"/ja-jp/responsibility/","openInNewWindowText":null}},{"title":"疾患情報サイト（患者さま向け）","content":"疾患情報サイト（患者さま向け）をご紹介します。","image":{"src":"/media/w4imcuz0/peckham_05_2022_patient_garden_russel_josie_rsv_04_oh_27128.jpg?rxy=0.41245136186770426,0.391812865497076&width=427&height=533&format=webp&quality=100&v=1dc0141d752c4a0&hmac=1753deebda5b1a35cd4662c7380ff231e7cc1a0ec53614ecfc9a14ef50c2d962","alt":"疾患情報サイト（患者さま向け）","darkModeSrc":"/media/w4imcuz0/peckham_05_2022_patient_garden_russel_josie_rsv_04_oh_27128.jpg?rxy=0.41245136186770426,0.391812865497076&width=427&height=533&format=webp&quality=90&v=1dc0141d752c4a0&hmac=eebb7ab703fbe809f40dc5d3d929ff12da70e3f7c6979cb06b70c93822135993"},"link":{"text":"Disease Information","href":"/ja-jp/news/in-focus/disease-information/","openInNewWindowText":null}}],"hidePageDescription":false,"useGreyBackground":false}]}